Bio News
$7 billion investment to secure a lead in next-generation technology
Eli Lilly is investing $7 billion (approximately $10 billion) in China’s cell and gene therapy (CGT) market to secure in vivo CAR-T generation technology. The investment will focus on next-generation technology that creates CAR-T cells directly inside the patient’s body, bypassing the complex ex vivo manufacturing process. Through the large-scale investment, Lilly plans to establish a leading position in China’s CGT market as its regulatory environment becomes more established.
BIOBOOK TEAM
biobookmedia@biobook.co.krMerck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
